Articles published by Pfizer Inc.
![](https://mms.businesswire.com/media/20240229001671/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20240229807323/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSVO® for RSV in Older Adults
February 29, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20240226718778/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
February 26, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20240216443188/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
European Commission Approves Pfizer’s VELSIPITY® for Patients with Moderately to Severely Active Ulcerative Colitis
February 19, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20240215326427/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20240202234166/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20240130420927/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
January 30, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20240125523192/en/2009998/5/logo_Astellas_Horizontal_FullColor_CMYK.jpg)
![](https://mms.businesswire.com/media/20240109145168/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Recommends Shareholders Reject the Below-Market Mini-Tender Offer by TRC Capital Investment Corporation
January 10, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20240109858951/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20231221936013/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20240102942713/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
January 02, 2024
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231219651611/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to View and Listen to Webcast of January 30 Conference Call with Analysts
December 19, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231215417518/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20231213858048/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Declares First-Quarter 2024 Dividend
December 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231213759493/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Completes Acquisition of Seagen
December 14, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231213173781/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Provides Full-Year 2024 Guidance
December 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231212889916/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Receives All Required Regulatory Approvals to Complete the Acquisition of Seagen
December 12, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231211991010/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
FDA and EMA Accept Marstacimab Regulatory Submissions for the Treatment of Hemophilia A and B
December 11, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231209134253/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Marstacimab Phase 3 Data Presented at ASH 2023 Demonstrate Significant Bleed Reduction in Hemophilia A and B
December 09, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231130525774/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
European Commission Approves Pfizer’s ELREXFIO® for Relapsed and Refractory Multiple Myeloma
December 08, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231130108413/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Announces Topline Phase 2b Results of Oral GLP-1R Agonist, Danuglipron, in Adults with Obesity
December 01, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231121344489/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 21, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231102445115/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Highlights Scientific Advances from Growing Hematology Portfolio at American Society of Hematology Annual Meeting
November 02, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231102674840/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
November 02, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231031512205/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Reports Third-Quarter 2023 Results
October 31, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231026448732/en/1670922/22/pfizer-biontech-logos.jpg)
![](https://mms.businesswire.com/media/20231019164717/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
![](https://mms.businesswire.com/media/20231013643494/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
Pfizer Amends U.S. Government Paxlovid Supply Agreement and Updates Full-Year 2023 Guidance
October 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
![](https://mms.businesswire.com/media/20231012073213/en/1045874/5/Pfizer_Logo_Color_RGB_APPROVED.jpg)
U.S. FDA Approves Pfizer’s VELSIPITY™ for Adults with Moderately to Severely Active Ulcerative Colitis (UC)
October 13, 2023
From Pfizer Inc.
Via Business Wire
Tickers
PFE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.